Advances in treatment of glucocorticoid-induced osteoporosis
| Autor: | Emory Hsu, Mark S. Nanes |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Bone density Endocrinology Diabetes and Metabolism medicine.medical_treatment Osteoporosis 030209 endocrinology & metabolism Bioinformatics Article 03 medical and health sciences 0302 clinical medicine Endocrinology Bone Density Teriparatide Internal Medicine Humans Medicine Glucocorticoids Monitoring Physiologic Bone mineral Nutrition and Dietetics Alendronate Bone Density Conservation Agents Diphosphonates business.industry Bisphosphonate medicine.disease 030104 developmental biology Denosumab Spinal Fractures Preventive Medicine business Osteoporotic Fractures medicine.drug |
| Zdroj: | Current Opinion in Endocrinology & Diabetes and Obesity. 24:411-417 |
| ISSN: | 1752-296X |
| DOI: | 10.1097/med.0000000000000368 |
| Popis: | The aim of this study is to summarize monitoring, prevention and treatment options of glucocorticoid-induced osteoporosis for patients on chronic glucocorticoid therapy.Recent meta-analyses highlight the efficacy of bisphosphonate use in improving bone mineral density and in reducing vertebral fractures in the setting of long-term glucocorticoid use. A new study has now shown that alendronate also reduces the risk of hip fracture in glucocorticoid use. Emerging data indicate that teriparatide and denosumab also reduce the risk of osteoporotic fracture in glucocorticoid-induced osteoporosis.Glucocorticoid use is a leading cause of secondary osteoporosis; however, patients at risk of glucocorticoid-induced osteoporosis are often not evaluated or treated in a timely manner. Patients on a dose equivalent of 2.5 mg prednisone or greater for 3 months or longer duration should have their fracture risk assessed. Those at moderate or high risk should start bisphosphonate therapy, or if contraindicated, a second-line agent such as teriparatide or denosumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|